% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

silent_wealth 15 posts  |  Last Activity: Mar 17, 2015 2:36 AM Member since: Jul 24, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • silent_wealth silent_wealth Mar 17, 2015 2:36 AM Flag

    You sound like a nutcase cloud, but I have observed an unusual accumulation pattern myself over the past 2-3 trading days; a rapidly accelerating Money Flow Index. They seem to be pumping quite a bit of cash into this price region while succeeding in holding it down by the time we close the day. In most cases this eventually results in an explosive move to the upside- and you're right, the intensity here is a rare phenomenon.

  • silent_wealth silent_wealth Mar 4, 2015 4:07 PM Flag

    My 3 Day Target says 24.60
    Lets see what it closes at on Friday?.....

    Sentiment: Strong Buy

  • Think about it. Aetna just forced the starting gun to be fired by crossed the line AHEAD of USPSTF's rating - in what will soon evolve as a full fledged race for cost savings competition between the insurers. By offering their customers more by way of services or lowered premiums as a result of the longterm savings, Aetna will be able to steal business from their competitors. In my opinion, the other National Insurers will begin to follow suit adopting coverage for CG in very short order, and as a result of this, we will see a cascade of short covering as the hedge fund managers realize that they are in an untenable position that cannot be "fixed" by simply borrowing shares to pummel the market now, only to be forced to return them later. The risk, of course, is that they'll be doing so at much higher prices once adoption starts to snowball.

    Sentiment: Strong Buy

  • silent_wealth silent_wealth Feb 17, 2015 9:00 PM Flag

    True Bcloaner, but I am a short.
    Now its your turn. YOU look at it and tell that we won't see this stock pushed/pulled/manipulated back up above $12 again. Barring any dismal news news, super positvie consumer adoption and the announcement of new drugs being developed for the dreamboat inhaler, again, might be the catalyst to keep us from going anywhere south of $12, still.

    Sentiment: Strong Buy

  • silent_wealth silent_wealth Feb 5, 2015 6:35 PM Flag

    Its true, these desperate short clowns do indeed try to paint the chart in AH but it is meaningless. Totally meaningless. Read todays SEEKING A article if you need a little encouragement. NOT A DIME BELOW 20.00!!

    Sentiment: Strong Buy

  • After 10 years of reasearch, over 1 Billion invested the Official Launch for the worlds first fast acting inhalable insulin is TODAY.
    Now Available
    Afrezza® Inhalable Insulin
    Afrezza® is a rapid acting insulin inhaled at mealtimes to improve blood sugar control in adult patients with diabetes. Do not use Afrezza® as a substitute for long-acting insulin; Afrezza® must be used in combination with long-acting insulin in patients with type 1 diabetes. Do not use Afrezza® to treat diabetic ketoacidosis. Afrezza® is not recommended in patients who smoke or who have recently stopped smoking. So ask your doctor if Afrezza® could be right for you.

    Afrezza (insulin human) Inhalation Powder Inhaler
    Sign up for Afrezza® information & updates
    If you’re a person with diabetes, you can learn more about Afrezza® by signing up below.
    Sanofi U.S. respects your interest in keeping your personal information private. We will not sell or rent your information to any outside mailing lists.
    Download PDF

    Prescription Afrezza® is a rapid-acting inhaled insulin used to treat adults with type 1 and type 2 diabetes for the control of high blood sugar.

    Sentiment: Strong Buy

  • Paris and Valencia, Calif. - February 3, 2015 - Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes.
    "Many people living with diabetes are not able to control their blood sugar on their current medications and may benefit from using insulin. Now they have another option to administer insulin that is not an injection," said Dr. Janet McGill, M.D., Professor of Medicine at Washington University School of Medicine in St. Louis and Afrezza clinical trial investigator. "This delivery option may help change the dialogue between health care professionals and people living with diabetes about initiating or intensifying insulin therapy."

    -Afrezza is an important addition to Sanofi's growing diabetes portfolio of integrated, personalized offerings, and it is one that highlights our dedication to bringing innovative therapies to people with this disease," said Pierre Chancel, Senior Vice President Diabetes Division, Sanofi. "There is a recognized need for an insulin that doesn't require an injection, and our organization is committed to making this new treatment option available to patients."

    "We are extremely proud to see the many years of work that went into developing Afrezza culminate in the day when it is now available to help people manage their diabetes," stated Alfred Mann, Executive Chairman, MannKind Corporation.
    About Afrezza
    Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and delivers insulin quickly to the bloodstream............

    Sentiment: Strong Buy

  • silent_wealth silent_wealth Jan 29, 2015 7:26 PM Flag

    Such as?
    Information that we have been receiving thus far only more up to date. For example, a more recent head count of prescribing physicians. Fresh updates on the number of kits ordered but there was no compliance, number of tests performed that identified positive, number of tests ordered by doctors not yet in our network. An estimate on gross margins and of course one major tell all would be an increase in capex, new hire statistics etc etc. It doesn't have to involve actual numerical targets such as typical "guidance" to be of great benefit to shareholders attempting to determine the best size of their holdings or the covering of their short positions as 27 million such shares short exist as a large portion of the float.

    Sentiment: Strong Buy

  • silent_wealth silent_wealth Jan 29, 2015 3:15 PM Flag

    I believe he was referring to given dollar amount estimates on next quarters and full year revenue and profits. When I refer to guidance, I am including all that is "inferred" by what he does tell us. There is plenty of info that falls outside of the realm to which I believe to be referring Citadel.

    Sentiment: Strong Buy

  • Is enough evidence of endorsement, that a big GONG sounds revealing the bad (economic and moral) decision made by the 2 biggest private insurers. Both Aetna (NYSE:AET) and United Health (NYSE:UNH) have stated they do not currently offer coverage for Cologuard.

    A lot has changed as the word gets out, but two months ago, per the December 1, 2014 United Health Medical Policy, "Fecal DNA testing for colorectal cancer screening and/or monitoring is unproven and not medically necessary." The Medical Policy further states that the optical colonoscopy is recommended by the United States Preventative Services Task Force (USPSTF) and United Health plans to follow these recommendations.

    Aetna came to the same conclusion that testing is not medically necessary, however, they offered a different reason. According to Aetna's clinical bulletin, Colonoscopies every 10 years, Double Contrast Barium Enema (DCBE) every 5 years or Sigmoidoscopy every 5 years follow current recommendations and are covered. Screening through stool using Molecular Genetic techniques, including Cologuard, are experimental/investigational due to insufficient evidence in peer reviewed literature.

    Should either of these two reverse their stance on or before the next conference call, you can be sure that the company will be upping their guidance and the brokerages will be raising their targets as well. In most cases, I expect this number to double - and I think Im being conservative. It may not happen in time for this quarters call, but I have little doubt that serious inroads have been made and it wont' be long thereafter that we hear this best of all news.

    Sentiment: Strong Buy

  • Reply to

    Yahoo is deleting selected posts...hummm

    by individuaione Jan 25, 2015 12:25 PM
    silent_wealth silent_wealth Jan 26, 2015 1:35 AM Flag

    Indi, If you find that your posts are being deleted.
    Try logging out of your account as soon as you've made the post. They are logging in as YOU to remove your "own" post. It works!

    Sentiment: Strong Buy

  • - EARLY detection there of.

    EXPANSION of Cologuard

    Sentiment: Strong Buy

  • Initial EU Launch

  • silent_wealth by silent_wealth Jan 14, 2015 12:17 PM Flag

    Very Impressive - no bs!
    10,000 Physicians
    10 million FIT and FOTB tests ordered last year.
    Continued growth of adoption by physicians, and patient compliance.

    Future: To be included on Affordable Care Act

    Sentiment: Strong Buy

  • If you sold because of this yesterday then SHAME ON YOU!
    Go back to your homework and do some study. This is a NEW product that was barely available during Q4. In case it hasn't occurred to you, dealing with the issue is one that is most procrastinated over of all medical procedures. Why? I would suggest it's related to the stigma of one's own stool, but more over a lingering relic of the reluctance surrounding colonoscopies. But it's all about the guidance this quarter, moreso than the average company - and that's a certainty. Wait to hear what the company has to say on Wednesday and then see if you really should have sold. My guess on that answer will be a "hell NO", but time will tell.

    Sentiment: Strong Buy

2.66-0.010(-0.37%)Apr 1 3:59 PMEDT